Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NewGam in primary immunodeficiency diseases
ISRCTN05425999Phase 3Completed
- Sponsor
- Octapharma
- Start
- Dec 2009
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of subcuvia in Immunogenetic disorder, common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA) (2 arms), sponsored by Octapharma. Primary endpoint: Efficacy in preventing serious bacterial infections. Started Dec 2009; status: completed.
02
Drugs
subcuvia
03
Conditions
Immunogenetic disordercommon variable immunodeficiency (CVID)X-linked agammaglobulinemia (XLA)
Beyond the preview
Go deeper on ISRCTN05425999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN05425999.